Zealand Pharma A/S (LON:0NZU)

Market Cap	2.71B
Revenue (ttm)	6.25M
Net Income (ttm)	-132.95M
Shares Out	n/a
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	3.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,081
Average Volume	11,271
Open	332.60
Previous Close	343.25
Day's Range	315.10 - 333.40
52-Week Range	315.10 - 964.50
Beta	n/a
RSI	33.14
Earnings Date	Aug 14, 2025

About Ligand Pharmaceuticals

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 335
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZU

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.